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Cardiac transplantation offers definitive therapy for selected
patients with end-stage heart failure and thus provides
significant improvements in survival in these recipients.
Heart transplantation comes with a cost, however, resulting
from the actual transplantation procedure, the subsequent
allo-immune response to the transplant and the immuno-
suppressive medications required to keep the allo-immune
response under control. Patients are subject to different
types of morbidities after transplant compared to pre-
transplant. The medical consequences of the allo-immune
response or rejection and the side effects of immuno-
suppressive medications—in particular, the mainstay immuno-
suppressive agent cyclosporine—have been well described
(1). The consequences of denervation have been studied, in
particular, with regard to the blunted exercise response and
subsequent limitations to maximal exercise that have been
observed posttransplantation (2–4). The role of denervated
heart in other posttransplant sequelae, such as hypertension,
has not been well defined.
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Earlier explanations for the mechanisms of the hyperten-
sion observed in heart transplant recipients have primarily
focused on the crucial immunosuppressive agent, cyclospor-
ine. Cyclosporine has been implicated in activation of the
sympathetic nervous system in heart transplant recipients,
resulting in hypertension (5). Additionally, cyclosporine has
been well documented as a cause of chronic nephropathy,
and this too can result in hypertension (6). However,
patients who do not receive cyclosporine often develop
hypertension (7). This raises the possibility that alternative
mechanisms may account for the development of hyperten-
sion in cardiac transplant recipients regardless of their
immunosuppressive regimen. Braith and colleagues (8–10)
have previously shown that infusing saline into heart trans-
plant recipients resulted in elevations in systolic and dia-
stolic blood pressures, in response to volume expansion from
the saline infusion. In particular, extracellular fluid expan-
sions on the order of 14%, which can occur routinely in the
clinical setting of cardiac transplant recipients, can result in
hypertension. It has also been shown that heart transplant
recipients have an abnormal and decreased response to
saline infusion, with a decreased natriuretic response (8).
The etiology of this was not exactly clear. Prior evidence
suggested the possibility of abnormal responsiveness of the
renin-angiotensin-aldosterone system (RAAS) to fluid re-
tention in heart transplant recipients resulting in hyperten-
sion (8). The disease occurs rapidly after transplantation,
usually within a matter of weeks to months, and its
pathogenesis remains complex (7,11). Often, hypertension
in heart transplant recipients does not respond to single
agents and requires multiple antihypertensive drugs (7,11).
In the present study by Braith and colleagues (12), stable
heart transplant recipients receiving cyclosporine had their
antihypertensives stopped, after which their blood pressure,
RAAS profile, including plasma angiotensin II, and aldo-
sterone, and vasopressin, atrial natriuretic peptide (ANP),
urine flow rate, and urinary salt excretion were assayed
during saline infusion. These parameters were measured
again more than 16 weeks after the baseline studies and after
pretreatment with the angiotension-converting enzyme
(ACE) inhibitor captopril followed by another saline infu-
sion. Stable liver transplant recipients taking cyclosporine
went through the same two-part protocol as controls. Saline
infusions in heart transplant, but not liver transplant,
patients resulted in elevations in systolic and diastolic
pressures, and in angiotensin II and aldosterone levels that
were abolished with pretreatment with captopril. Urine flow
rate and urinary sodium secretion were significantly lowered
in heart transplant recipients during salt infusion compared
to baseline, but this too was reversed with ACE inhibition.
The investigators (12) conclude that salt expansion failed to
suppress RAAS in cardiac transplant recipients owing to
denervation of cardiac volume receptors.
It has previously been demonstrated that heart transplant
patients appeared to have RAAS that does not suppress
with volume loading. Furthermore, volume expansion has
been associated with hypertension in heart transplant pa-
tients, and blood pressure appears to be responsive to salt in
these patients (10). Furthermore, plasma renin activity and
ANP are chronically elevated in heart transplant recipients,
indicating abnormal responsiveness of the cardiac mechano-
receptors that regulate elaboration of these hormones (13).
The present study ties all these findings into a unified
pathophysiologic framework with clinical implications. The
volume expansion from salt loading in heart transplant recip-
ients fails to suppress RAAS, and the net result is hypertension
and decreased urinary salt excretion and urine flow rate. Liver
transplant recipients did not show these findings despite also
receiving cyclosporine with similar trough level. This would
indicate that the volume-dependent form of hypertension seen
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in heart transplant recipients is a result of failure of cardiac
volume receptors to respond to changes in loading conditions
as a result of cardiac denervation after heart transplantation.
Administration of ACE inhibitors to ablate the RAAS re-
versed these observations.
This work has important implications for the manage-
ment of hypertension in heart transplant recipients. It would
appear that ACE inhibition would be the treatment of
choice for hypertension in cardiac transplant patients. This
class of drugs would be ideal in blunting the effects of the
neurohormonal systems that fail to respond to volume expan-
sion. Further, Braith’s study raises another intriguing issue,
which is that aggressive restriction of salt intake may be a
successful strategy for managing hypertension in heart trans-
plant recipients. This strategy would be akin to that used in
patients with congestive heart failure (though for different
purpose) but would represent a departure from the standard
management of heart transplant recipients at many centers.
This would require patient education to enable physiologically
guided therapy for hypertension in heart transplant patients. It
is thus possible that nonpharmacologic therapy with salt
restriction could result in improvement in hypertension in
these individuals.
Several interesting questions remain regarding the poten-
tial mechanism of salt-expansion-induced hypertension in
heart transplant recipients and the role of RAAS. One
would expect that this form of hypertension would be as
likely to occur in patients receiving tacrolimus as in those
receiving cyclosporine, yet patients receiving the latter are
more likely to be hypertensive (14). Thus, it would appear that
cyclosporine has an additive and perhaps independent effect on
blood pressure. Further, cardiac reinnervation has been dem-
onstrated in heart transplant recipients several years out from
transplant by assessing tyramine-induced release of norepi-
nephrine (15). It would be interesting to see whether these
patients develop a RAAS that is responsive to volume loads.
Finally, many transplant centers have been performing
bi-caval heart transplants, thus essentially transplanting
almost the entire donor heart. The present study involved
patients with bi-atrial transplants. Though the issue of dener-
vation would still be present, differences in response to volume
loads may be identified in bi-caval transplant recipients.
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